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THE AIDS VACCINE: LEGISLATION TO LIMIT
MANUFACTURER'S LIABILITY
I. INTRODUCTION
The first reports of a disease affecting the immune system of homo-
sexual men emerged over ten years ago.1 The medical community
quickly recognized a new and potentially devastating threat to the health
of the world, acquired immunodeficiency syndrome (AIDS).2 Although
researchers have identified the infectious agent responsible for AIDS,
human immunodeficiency virus (HIV), the scientific community has con-
tinued its diligent study of the etiology of the disease. The ultimate goal
of researchers remains eradication of AIDS through the production of a
safe and effective vaccine.3
The existence of several formidable barriers blocks the realization of
this goal. For example, the target of the virus, the immune system, is
also the target of the potential vaccine.4 In other words, infection with
the virus causes deterioration of the very system which the vaccine would
be designed to stimulate. Thus, the candidate vaccine must successfully
block the interaction between the virus and the immune system. Early
research efforts focused, therefore, on gaining an understanding of the
host immune response to HIV in order to design a vaccine which would
trigger the appropriate protective response.5
Perhaps the greatest barrier to the production of a successful vac-
cine, however, may not be imposed by the virus, but rather by the United
States legal system. Potential legal liability for injuries resulting from a
1. Evidence of previously considered rare opportunistic infections and sarcomas, usually lim-
ited to patients suffering from impairments of the immune system, first appeared in two reports.
Centers for Disease Control, Pneumocystispneumonia-Los Angeles, 30 MORBIDITY & MORTALITY
WKLY. REP. 250 (1981); Centers for Disease Control, Kaposi's Sarcoma and Pneumocystis Pneumo-
nia Among Homosexual Men-New York City and California, 30 MORBIDITY & MORTALITY
WKLY. REP. 305 (1981).
2. See Michael S. Gottlieb et al., Pneumocystis Carinii Pneumonia and Mucosal Candidiasis in
Previously Healthy Homosexual Men: Evidence of a New Acquired Cellular Immunodeficiency, 305
NEW ENG. J. MED. 1425 (1981).
3. Dani P. Bolognesi, Progress in Vaccines Against AIDS, 246 SCIENCE 1233 (1989).
4. EDWARD S. GOLUB & DOUGLAS R. GREEN, IMMUNOLOGY: A SYNTHEsIs 684-702
(1991).
5. See Ammar Achour et al., HGP-30, a Synthetic Analogue of Human Immunodeficiency
Virus (HIV) p17, Is a Target for Cytotoxic Lymphocytes in HIV-Infected Individuals, 87 PROC.
NAT'L ACAD. Scl. USA 7045 (1990). See also Per Putkonen et al., Prevention of HIV-2 and SIFsm
Infection by Passive Immunization in Cynomolgus Monkeys, 352 NATURE 436 (1991).
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vaccination severely restricts the large pharmaceutical manufacturers'
willingness to participate in the development and testing of a vaccine
against the AIDS virus.6 This article analyzes current legislative at-
tempts to reduce the negative impact of tort liability on vaccine produc-
tion and offers suggestions for future legislation. This legislation must
not only grant immunity from tort liability to vaccine researchers and
manufacturers, but also provide a source of funding to compensate the
few inadvertent victims of a process designed to protect and save the lives
of many.
II. BACKGROUND AND DEVELOPMENT
A. The Need for an AIDS Vaccine
The incidence of AIDS increased at an alarming rate during the ini-
tial decade following its identification. In 1982, 1080 cases of AIDS were
reported to the Centers for Disease Control (CDC).7 Through June of
1991, 182,834 cases had been reported.8 During the middle of 1987, the
reported incidence of AIDS in the United States began to decrease.9 In
fact, new cases of AIDS reported to the CDC for the first 6 months of
199110 show a marked reduction from the number for 1991 predicted in
1986 based on epidemiological data available at that time." This decline
may be due to the identification of the modes of transmission of HIV and
the groups at risk of becoming infected, as well as the subsequent educa-
tion of these groups concerning the dangers of the disease and means of
avoiding exposure. 2 Although the declining infection rate in the United
States is encouraging, the disease continues to spread rapidly in many
6. Dr. Jonas Salk, the researcher credited with developing the polio vaccine, informed a meet-
ing of the Association of Trial Lawyers of America (ATLA) that legal concerns threaten a vaccine's
marketability, and that manufacturers fear that "someone will come along and make some kind of
claim regardless of whether or not there is any scientific basis for it." Andrew Blum, AIDS Research
Faces Hurdle: Who's Liable?, NAT'L L.J., July 29, 1991, at 36. See also Laurie Garrett, The Waiting
Game in AIDS Research; Giant Drug Companies are Watching the Little Guys in the Quest for a
Vaccine, NEWSDAY, Sept. 18, 1990, at 5.
7. Centers for Disease Control, HIVIAIDS Surveillance Report, July 1991, at 1, 13.
8. Id. at 5, 12.
9. Centers for Disease Control, Update: Acquired Immunodeficiency Syndrome-United
States, 1989, 39 MORBIDrrY & MORTALITY WKLY. RaP. 81, 83 (1990).
10. Centers for Disease Control, supra note 7, at 5. For the first 6 months of 1991, 9,885 new
cases of AIDS were reported to the CDC. Id. at 13.
11. W. Meade Morgan & James W. Curran, Acquired Immunodeficiency Syndrome: Current
and Future Trends, 101 PuB. HEALTH REP. 459, 460 (1986). Data available in 1986 indicated
37,000 new cases of AIDS could be expected for a six month period in 1991. Id. at 461.
12. See Centers for Disease Control, supra note 7, at 18.
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parts of the world, especially in developing countries.13 Thus, the need
for continued research directed toward prevention and, ultimately, eradi-
cation of the disease has not diminished.
The loss to the U.S. economy, in terms of lost life years, is stagger-
ing. 4 AIDS most frequently strikes young men, age twenty-five to forty-
four years. 5 The median age in this range is thirty-five years. Assuming
a death at thirty-five years of age represents thirty years of lost life, then
the 24,600 deaths caused by AIDS in 199016 accounted for 738,000 years
of lost life. In 1989, it was estimated that the net value of losses to the
economy attributable to lives cut short by the AIDS virus was more than
$600,000 per person." Through June 1991, the CDC had reported
114,338 adult deaths from AIDS. That translates to roughly $70 bil-
lion lost to the economy. Of course, the true loss cannot be measured in
economic terms alone.
Prevention of these losses can be effected by halting the spread of
AIDS. The traditional approach to prevention of a disease caused by a
virus is to develop a vaccine. With a view toward preventing AIDS, it is
necessary to analyze whether the development of a vaccine against AIDS
is a realistic goal. Resolution of this question requires a basic under-
standing of vaccines and the science of immunology. 9
B. Vaccines and the Immune System
A vaccine is a preparation designed to stimulate the immune system,
that part of the body responsible for eliminating pathogens and distin-
guishing "self" from "non-self," to neutralize the pathogen responsible
for the disease.2' Specific cells within the immune system are capable of
recognizing foreign molecules, antigens, on the surface of the infectious
agent and remembering the antigen in case of subsequent exposure.21
13. See Carole Levine, AIDS and the Ethics of Human Subjects Research, in AIDS AND ETHIcs
77, 99 (Frederic G. Reamer ed., 1991).
14. For a detailed analysis of the financial burden of the AIDS epidemic, see Anne A. Scitovsky
& Dorothy P. Rice, Estimates of the Direct and Indirect Costs of Acquired Immunodeficiency Syn-
drome in the United States, 1985, 1986, and 1991, 102 PuB. HEALTH REP. 5 (1987).
15. See Centers for Disease Control, supra note 7, at 12.
16. See id. at 13.
17. Henry T. Greely, AIDS and the American Health Care Financing System, 51 U. Prrr. L.
REV. 73, 74-75 (1989).
18. See Centers for Disease Control, supra note 7, at 13.
19. See generally Joseph Earley, Can Biotechnology Immunize Vaccine Manufacturers from the
Products Liability Crisis?, 30 JURIMETRICS J. 351, 353-56 (1990) (providing general background
information on the immune system and vaccines). See also GOLUB & GREEN, supra note 4, at 684.
20. See Earley, supra note 19, at 353-54.
21. See id. (describing the special cells of the immune system activated upon recognition of the
1992]
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The ability of the immune system to remember an antigen and
mount a rapid response when confronted by it upon subsequent expo-
sures, supplies the foundation for the functional success of vaccine ther-
apy.22 Basically, the vaccine represents a "safe," non-infective form of
the antigen which triggers the primary immune response, leaving the
vaccinee's immune system primed for a more rapid response upon subse-
quent exposure to a pathogenic form of the antigen.23
Vaccines in use today can be divided into two broad groups: con-
ventionally produced and biotechnologically produced. Conventional
vaccines include those utilizing either attenuated (live, modified) patho-
gen;24 whole, killed pathogen;2" or a purified fraction of the pathogen.26
Although all three types of conventional vaccines are highly effective in
preventing infection upon subsequent exposure to the pathogen, each of
these vaccines is also capable of causing the infectious disease it was in-
tended to prevent.27
The second major group of vaccines, biotechnologically synthesized
vaccines ("biotech" vaccines), apply the most recent discoveries in mo-
lecular biology to principles of immunology to produce efficient and, the-
oretically, safer vaccines.28 The increased safety potential arises because
the antigen delivered to trigger the primary immune response has been
synthetically produced. 29 In other words, the antigen is artificially de-
rived rather than naturally derived from the actual pathogen. Thus, the
biotech vaccines confer immunity to a pathogen without exposure to any
form of the pathogen itself30 and avoid the inherent danger associated
antigen, T-cells (thymus-derived lymphocytes), which proliferate and differentiate into three func-
tionally specialized types of T-cells: those responsible for killing cells which carry the antigen
(cytotoxic T-cells), those which remember the antigenic segments (T memory cells), and those which
can suppress response to the antigen (T suppressor cells)). See also GOLUB & GREEN, supra note 4,
at 695-98 (describing components of the immune system).
22. See Earley, supra note 19, at 354.
23. See id. at 354-55.
24. See id. at 355. An example of an attenuated live pathogen vaccine is the Sabin polio vac-
cine. See generally id. at 355-56.
25. The Salk polio vaccine relies on whole, killed pathogen. See generally id.
26. Hepatitis B and whooping cough (pertussis) vaccines exemplify vaccines composed of puri-
fied fractions of the pathogen. Id.
27. See generally Reyes v. Wyeth Lab., 498 F.2d 1264 (5th Cir. 1974) (involving a live, modi-
fied vaccine, the Sabin polio vaccine, which remodified to the pathogenic form), cert. denied, 419
U.S. 1096 (1974); Gottsdanker v. Cutter Lab., 6 Cal. Rptr. 320 (Cal. Dist. Ct. App. 1960) (involving
a killed whole virus vaccine, the Salk polio vaccine, which contained live virus); Carlenstolpe v.
Merck & Co., 819 F.2d 33 (2d Cir. 1987) (involving an allegation that a purified fraction vaccine,
Hepatitis B, contained an undisrupted pathogen).
28. See Earley, supra note 19, at 362.
29. See id at 364.
30. See id. at 362-65.
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with conventional vaccines, inadvertent infection with the infectious
agent.
Although the conventional approach to production of an HIV vac-
cine has been proven valuable in animal studies designed to increase un-
derstanding of the human immune response to HIV, it is generally
accepted that the HIV vaccine will utilize a recombinant DNA-derived
antigen.31 Biotech vaccines are considered safer than conventional vac-
cines.32 However, they are not risk-free.33 Therefore, the potential for
legal liability of the manufacturer cannot be discounted.
C. Efforts to Produce an AIDS Vaccine
Although several unanswered questions haunt researchers,34 the sci-
entific community is optimistic about the future of an AIDS vaccine.
This optimism results from studies which successfully demonstrate that
conventional killed-virus vaccines have worked efficiently in animal mod-
els,35 that substantial progress has been made in the identification of im-
munological targets on both the free virus and the infected cell,36 and
31. Id.
32. See id. at 364.
33. See id. at 365-67. A non-defective biotech vaccine may prove to be unreliable due to the
unique quality of each individual's immune response. For example, a vaccine presenting a narrow
target may not elicit the desired immune response in each individual. In addition, it is possible that
the immune system could select an irrelevant site on the antigen, leaving the immune system un-
primed and unable to respond to the infectious agent upon subsequent exposure. Id.
34. See Andreas Meyerhans et a., Temporal Fluctuations in HIV Quasispecies In Vivo Are Not
Reflected by Sequential HIVIsolations, 58 CELL 901 (1989). This study cautions against over-inter-
pretation of data collected from in vitro conditions which may not accurately reflect the in vivo
situation. See id. at 906-07. See also Bolognesi, supra note 3, at 1234. Some efforts designed to
prevent infection have actually enhanced disease progression. These results indicating enhanced
disease progression rather than prevention are limited to in vitro systems.
35. See generally Michael Murphey-Corb et al., A Formalin-Inactivated Whole SIV Vaccine
Confers Protection in Macaques, 246 SCIENCE 1293 (1989) (demonstrating the utility of the simian
model which couples the similarities in viral composition of SIV, simian immunodeficiency virus,
and HIV with the similarities of disease symptoms in rhesus monkeys and humans); R. C. Desrosiers
et al., Vaccine Protection Against Simian Immunodeficiency Virus Infection, 86 PRoc. NAT'L ACAD.
Sci. USA 6353 (1989) (describing the advantages of the simian model which include a high mortality
rate and a relatively rapid onset of disease symptoms following exposure to SIV); Putkonen et al.,
supra note 5, at 436 (describing data which indicate that monkeys treated with various forms of an
inactivated whole virus receive protection from subsequent challenges with live SIV); E. Stott et al.,
Preliminary Report: Protection of Cynomolgus Macaques Against Simian Immunodeficiency Virus by
Fixed Infected-Cell Vaccine, 336 LANCET 1538 (1990) (describing data which indicate protection
against subsequent challenges attributable to an inactivated whole virus vaccine).
36. See generally Rebecca H.R. Ward et al., Prevention of HIV-i 111B Infection in Chimpanzees
by CD4 Immunoadhesin, 352 NATURE 434 (1991) (indicating that a special type of protein found on
the outer envelope of HIV, identified as gpl20, binds to its receptor, CD4, on the surface of a T-cell
to initiate the infection process); Daniel J. Capon & Rebecca H.R. Ward, The CD4-gp120 Interaction
and AIDS Pathogenesis, 9 ANN. REV. IMMUNOLOGY 649 (1991) (confirming that the focus of AIDS
therapeutics has become the CD4-gpl20 interaction, crucial to the progression of the disease due to
5
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that data have been generated indicating a favorable response by humans
to candidate immunogens.37
The AIDS research community continues to progress toward the
realization of a successful vaccine against HIV.38 With this progress has
come the first clinical trials39 in the United States involving human vol-
unteers for testing potential AIDS biotech vaccines. These trials began,
with the approval of the U.S. Food and Drug Administration (FDA), in
1988.4 The initiation of clinical trials in the United States brought to
the forefront the fears of the research community concerning the poten-
tial for legal liability connected with an AIDS vaccine,41 as well as ques-
tions concerning the ethics of using human volunteers in the trials.42 An
historical analysis of litigation by injured plaintiffs against vaccine manu-
facturers justifies the manufacturers' concern about liability exposure.
destruction of the CD4 subset of T-cells); Phillip Berman et al., Protection of Chimpanzees from
Infection by HIV-1 after Vaccination with Recombinant Glycoprotein gp120 but not gp)60, 345 NA-
TuRE 622 (1990) (reporting that the CD4-gpl20 interaction can be effectively blocked by pre-treat-
ing healthy chimpanzees with CD4 analogues that compete for gpl20 binding, and thus prevent
infection).
37. See generally Bolognesi, supra note 3, at 1234; Achour et al., supra note 5, at 7049 (demon-
strating that a synthetic peptide, HGP-30, may serve as a subvaccine candidate based on its ability to
induce cell-mediated immunity against HIV infection in volunteers participating in clinical trials in
Europe); 0. Picard et al., Aids Vaccine Therapy: Phase I Trial, 336 LANcET 179 (1990) (indicating
that AIDS patients in Paris immunized with preparations made from killed autologous cells infected
with recombinant vaccinia virus containing some HIV genes and gene products show an enhance-
ment of natural defense mechanisms).
38. Several "biotech" companies have made the development of an AIDS vaccine a top prior-
ity. See NATIONAL AIDS NETwoRK, AIDS INFORMATION SOURCEBoOm 213 (H. Robert Malinow-
sky & Gerald . Perry eds., 2d ed. 1989-90). However, only one "pharmaceutical giant," Bristol-
Myers Co., is conducting in-house AIDS vaccine research. Garrett, supra note 6, at 5.
39. Stefi Weisburd, Aids Vaccines: The Problems of Human Testing, 131 Sci. NEWS 329 (1987).
Clinical trials are divided into 3 phases. Phase I, involves fewer than 20 volunteers who are not
members of any of the high risk groups, during which the candidate vaccine's safety and ability to
trigger an immune response is evaluated. Phase II, involves 40 to 200 volunteers representing both
high and low-risk groups, during which dose-response and timing studies are conducted. Phase III,
requires a large number of volunteers in order to generate meaningful statistics, during which the
efficacy of the vaccine will be determined. Id. Only during Phase III testing is the volunteer exposed
to the pathogen, in this case, HIV. Id.
40. D.D. Edwards, Human Test of AIDS Vaccine Approved, 132 Sci. NEWS 116 (1988).
41. Weisburd, supra note 39, at 330. Weisburd predicts that:
Because of the unusually complicated nature of the AIDS virus, the urgency to develop a
vaccine against it and the potential for a vaccine's unforeseen side effects, it's likely that the
development of an AIDS vaccine will bring to a head long-standing legal problems associ-
ated with distributing vaccines in the country-especially since plaintiffs injured by vac-
cines have been increasingly successful in suing companies for damages.
Id.
42. Carol 0. Tacket & Robert Edelman, Ethical Issues Involving Volunteers in AIDS Vaccine
Trials, 161 . INFECTIOUS DISEASES 356 (1990).
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III. VACCINE MANUFACTURERS AND TORT LIABILITY
The use of the legal system and the concomitant application of tort
law to supply compensation for people injured by a vaccine provides an
interesting perspective to the development of the law of strict liability.
Cases involving injuries allegedly attributable to vaccines fall squarely
into that area of tort law initially proposed by Judge Traynor in his con-
curring opinion in Escola v. Coca-Cola Bottling Co.43 In that opinion,
Judge Traynor suggested that the manufacturer be held absolutely liable
if a defective product placed on the market without adequate inspection
caused injury.' This doctrine, known as strict liability, can now be
found in the Restatement (Second) of Torts § 402A.45
Although conventional vaccines have been proven invaluable to so-
ciety,46 it is technologically impossible to guarantee the elimination of the
risks of inadvertent infection or deleterious side effects.47 In other words,
vaccines could be classified as "unavoidably unsafe" products. Comment
k to § 402A11 establishes an exception to strict liability for products
which are, by their nature, unavoidably unsafe.49 It would appear, there-
fore, that comment k shelters vaccine manufacturers from strict liability.
However, two decisions in vaccine litigation, Davis v. Wyeth Labora-
tories, Inc.5 o and Reyes v. Wyeth Laboratories,"1 established that a vac-
cine manufacturer could be held strictly liable for a plaintiff's injuries in
spite of the shield provided by comment k if it failed to adequately warn
of the risks.5 2 The plaintiff in Davis, a thirty-nine year old man, received
the Sabin live attenuated polio vaccine at a mass immunization clinic.5 3
In Reyes, the plaintiff, an eight-month old girl, contracted paralytic polio
43. 150 P.2d 436 (1944).
44. Id. at 440.
45. RESTATEMENT (SECOND) OF TORTS § 402A (1) & (2)(a) (1965). "One who sells any prod-
uct in a defective condition unreasonably dangerous to the user or consumer... is subject to liability
for physical harm thereby caused to the ultimate user or consumer... [even though] the seller has
exercised all possible care in the preparation and sale of his product .... I d.
46. See generally Jenelle C. Prins-Stairs, The National Childhood Vaccine Injury Act of 1986:
Can Congressional Intent Survive Judicial Sympathy for the Injured?, 10 J. LEGAL MED. 703, 705-11
(1989) (providing an historical perspective on the significant role of vaccine technology).
47. See Earley, supra note 19, at 365-67. See also Garrett, supra note 6, at 5 (quoting Dr. Jonas
Salk, "There is no one-hundred-percent safe and effective vaccine. That's impossible.").
48. RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (1965).
49. Drugs and, specifically, vaccines are mentioned in comment k as examples of products
which carry risk of injury but are nonetheless in high demand due to the benefits conferred upon the
vast majority of recipients and to society as a whole. Id.
50. 399 F.2d 121 (9th Cir. 1968).
51. 498 F.2d 1264 (5th Cir. 1974), cert denied, 419 U.S. 1096 (1974).
52. Reyes, 498 F.2d at 1295; Davis, 399 F.2d at 131.
53. Davis, 399 F.2d at 122.
1992]
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after being administered a dose of the Sabin vaccine at a public health
clinic.54 In these cases, Wyeth failed to adequately warn the ultimate
consumers about the inherent risks of the vaccine and, therefore, failed to
comply fully with the requirements specified in comment k.55 In effect,
an inadequate warning itself is considered a product defect which results
in the product being "unreasonably dangerous as marketed."'56 Both
courts held Wyeth strictly liable for the plaintiffs' injuries.57 The Ameri-
can Academy of Pediatrics and the Conference of State and Territorial
Epidemiologists (CSTE) warned the Reyes court that this holding
threatened both the nation's preventive medicine programs and the
strength of public policy concerning the value of mass immunization
programs.
58
Another case involving the Sabin vaccine subsequent to Davis and
Reyes found the manufacturer strictly liable.59 In addition, lawsuits al-
leging negligence and products liability causes of action against manufac-
turers of other vaccines, specifically DPT (diphtheria, pertussis,
tetanus)' and swine flu,61 have also resulted in discouraging the manu-
facture of vaccines. For example, in Toner v. Lederle Laboratories,62 the
Court of Appeals for the Ninth Circuit held Lederle liable based on a
negligence cause of action for injuries sustained by the plaintiff, a three-
54. Reyes, 498 F.2d at 1274.
55. Davis, 399 F.2d 122, 125; Reyes, 498 F.2d at 1274. Comment k to § 402A provides in
pertinent part:
The seller of such products, again with the qualification that they are properly prepared
and marketed, and proper warning is given, where the situation calls for it, is not to be held
to strict liability for unfortunate consequences attending their use, merely because he has
undertaken to supply the public with an apparently useful and desirable product, attended
with a known but apparently reasonable risk.
RESTATEMENT (SECOND) OF TORTS § 402A cmt. k (emphasis added).
56. Comment h to § 402A provides that:
Where, however, he (the seller) has reason to anticipate that danger may result from a
particular use, as where a drug is sold which is safe only in limited doses, he may be
required to give adequate warning of the danger.., and a product sold without such
warning is in a defective condition.
RESTATEMENT (SECOND) OF ToRTs § 402A cmt. h (1965).
57. Reyes, 498 F.2d at 1295; Davis, 399 F.2d at 131.
58. Reyes, 498 F.2d at 1293.
59. See Givens v. Lederle, 556 F.2d 1341 (5th Cir. 1977). But see Percival v. American Cyana-
mid Co., 689 F. Supp. 1060 (W.D. Okla. 1987); Johnson v. American Cyanamid Co., 718 P.2d 1318
(Kan. 1986), aff'd, 758 P.2d 206 (Kan. 1988).
60. See Hurley v. Lederle Lab., 851 F.2d 1536 (5th Cir. 1988); Toner v. Lederle Lab. (Toner!),
779 F.2d 1429 (9th Cir.), cert denied, 485 U.S. 942 (1986); Toner v. Lederle Lab. (Toner I1), 828
F.2d 510 (9th Cir.), modified, 831 F.2d 180 (9th Cir. 1987).
61. See Unthank v. United States, 533 F. Supp. 703 (D. Utah 1982), aff'd, 732 F.2d 1517 (10th
Cir. 1984); Petty v. United States, 740 F.2d 1428 (8th Cir. 1984).
62. 828 F.2d 510 (9th Cir.), modified, 831 F.2d 180 (9th Cir. 1987).
[Vol. 27:757
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month old child, following vaccination with Lederle's Tri-Immunol, a
triple antigen vaccine for DPT.63 The plaintiff suffered a rare condition
of the spine, transverse myelitis." Although the exact cause of this con-
dition is unknown, the plaintiff's permanent paralysis was attributed to
the pertussis portion of the vaccine.6 5 The court held that Lederle had
negligently failed to develop a less toxic form of the pertussis vaccine,
Tri-Solgen, a fractionated cell product found to be unreliable which had
not received FDA approval. 6 The trial judge instructed the jury that
"[a] manufacturer of vaccines has the duty to exercise ordinary and rea-
sonable care not to expose the potential consumer to an unreasonable
risk of harm from the use of its products."'6 The jury found that Lederle
was liable for negligent failure to meet this standard of due care and,
therefore, awarded $1.1 million to the plaintiff. 8
IV. LEGISLATIVE EFFORTS TO PROTECT MANUFACTURERS
A. Federal Efforts
In 1976, fearing a swine flu epidemic and recognizing the reluctance
of vaccine manufacturers and their insurance underwriters to become in-
volved due to the risks of litigation,6 9 Congress enacted the National
Swine Flu Immunization Program of 1976 (Swine Flu Act).70 The Swine
Flu Act provided plaintiffs an exclusive remedy against the United
States, transferring liability for all injuries attributable to the swine flu
vaccine from the manufacturer to the United States.7 1 Mass immuniza-
tion against swine flu proceeded, and over 45 million people were
inoculated.7 2
The fact that many public school districts across the country require
that children entering school receive certain vaccinations convinced Con-
gress to address the question of liability for injuries resulting from these
63. Id. at 514.
64. Toner I, 779 F.2d at 1430.
65. Id.
66. Toner II, 828 F.2d at 512.
67. Toner 1, 779 F.2d at 1431. Toner I represents a trend in vaccine litigation where the jury is
asked to engage in a risk-benefit analysis of the manufacturer's product to determine whether the
benefit to the consumer outweighs the risks to the public. See Prins-Stairs, supra note 46, at 716.
68. Toner 1, 779 F.2d at 1430.
69. Evan L. Rosenfeld, The Strict Products Liability Crisis and Beyond: Is There Hope for an
AIDS Vaccine?, 31 JURIMETRICS J. 187, 198 (1991).
70. 42 U.S.C. § 247b(j)-(I) (1976), amended by Pub. L. No. 95-626, 92 Stat. 3574 (1978).
71. Id. § 247b(k)(1)(A).
72. Rosenfeld, supra note 69, at 199 (reflecting the strength of the endorsement of the vaccine
by the United States government).
1992]
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mandatory vaccines. 73 The resulting legislation, the National Childhood
Vaccine Injury Act of 1986 (NCVIA),74 requires that injured vaccine
recipients adjudicate their claims through the federal compensation pro-
gram before bringing a civil action in court.75 The Act requires that the
injury alleged to have been caused by the vaccine fall within the Vaccine
Injury Table defined in the Act.76 If the victim elects compensation from
the NCVIA, then the victim waives his right to subsequent civil actions
against the manufacturer." However, if the victim refuses compensation
under the Act, the victim is limited in any subsequent civil action to a
cause of action for negligent product preparation or distribution of the
vaccine.78
B. State Efforts
Two states, California 79 and Connecticut,"° have taken legislative
action to encourage production of an AIDS vaccine by granting immu-
nity to AIDS vaccine manufacturers. However, key differences exist be-
tween the two enactments. The California law was enacted to protect
vaccine manufacturers from strict liability claims by the creation of an
AIDS Vaccine Victims' Compensation Fund."' This fund will serve to
compensate applicants injured by an FDA-approved 2 AIDS vaccine.
Compensation is limited to $550,000 for direct medical costs, lost earn-
ings, and the amount required to compensate for non-economic losses,
including pain and suffering.8 3 The source of funds for the Compensa-
tion Fund will be a surcharge, not to exceed ten dollars, placed on the
sale of each unit of the vaccine sold or delivered, administered, or dis-
pensed in California."4 The California statute also provides for the crea-
tion of an AIDS Vaccine Guaranteed Purchase Fund designed to assure
73. See, eg., DEP'T OF HEALTH AND HUM. SERV., STATE IMMUNIZATION REQUIREMENTS
FOR SCHOOL CHILDREN 2 (1981); 132 CONG. REC. S17,347 (daily ed. Oct. 18, 1986) (statement of
Sen. Bradley).
74. 42 U.S.C.A. §§ 300aa-10 to -34 (West Supp. 1990).
75. See Rosenfeld, supra note 69, at 197 (interpreting 42 U.S.C.A. § 300aa-l l(2)(A)).
76. 42 U.S.C.A. § 300aa-14(a).
77. Id. § 300aa-22(b)-(c).
78. Id. § 300aa-22(b)(1).
79. CAL. HEALTH & SAFETY CODE § 199.45-.51 (West 1990).
80. 1991 Conn. Pub. Acts 91-349. On July 3, 1991, the state of Connecticut approved P.A. No.
91-349, S.H.B. No. 5624, An Act Concerning the Liability of Medical and Dental Interns, Residents
and Fellows of the University of Connecticut, Sponsors of Research Grants to Connecticut Institu-
tions of Higher Education and Persons Who Administer AIDS Vaccines. Id.
81. CAL. HEALTH & SAFETY CODE § 199.50(a) (West 1990).
82. Id. § 199.50(b)(1)(B).
83. Id. § 199.50(b)(3).
84. Id. § 199.50(o).
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purchase of at least 500,000 doses of an FDA-approved vaccine.85
While the California statute was drafted both to protect vaccine
manufacturers and to compensate victims of the vaccine after the realiza-
tion of an FDA-approved vaccine, the 1991 Connecticut statute was
designed to protect research scientists and institutions from liability dur-
ing the development and testing stages of the vaccine before FDA ap-
proval. 6 The manufacturer, research institution, or researcher is
immune from liability to a research subject for civil damages resulting
from administration of any AIDS vaccine.8 However, liability follows if
the injury was caused by gross negligence or reckless, willful, or wanton
misconduct by the manufacturer or researcher, or if the research subject
is inadequately warned of the risks associated with the research and does
not give informed consent.88 Observers are hopeful that this law "may
be the spark" necessary for serious review of the liability issue.89
V. ANALYSIS
A. Negative Impact of Previous Vaccine Litigation
The contribution of vaccines to our quality of life is incalculable.
Thousands of people have been spared death or the agony of a life
marred by paralysis. Parents of today rarely confront the hopeless de-
spair experienced by parents in the recent past when polio, measles, or
whooping cough outbreaks threatened the health of their children. Yet,
as a new health crisis ravages a portion of our population, the large phar-
maceutical companies are increasingly reluctant both to remain in the
85. Id. § 199.51. This portion of the statute should encourage the production of a vaccine
because "[t]he problem of a limited market is [a] significant obstacle to the production of an afforda-
ble vaccine." See Robert McKenna, The Impact of Product Liability Law on the Development of a
Vaccine Against the AIDS Virus, 55 U. CI. L. REV. 943, 963 (1988).
86. 1991 Conn. Pub. Acts 91-349, §§ 4-8.
87. Id. § 6.
88. Id.
89. See supra note 6.
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market9 ° and to research new products, 9 1 such as an AIDS vaccine.92
The negative impact of past vaccine litigation, such as Reyes, Davis,
and Toner accounts for the reluctance of the vaccine manufacturers.93
These decisions served to create legal uncertainty for the manufacturers
by finding liability in spite of compliance with marketing and safety re-
quirements. 94 Juries could still grant huge punitive damage awards
against the manufacturers although policy-makers, scientists, and FDA
doctors testify that the manufacturers achieved the highest level of safety
possible with current technology.95
Adding to the legal uncertainty faced by manufacturers and re-
searchers is the increased leniency with which courts have treated the
issue of causation. 96 For example, in Reyes,97 the jury found that the
vaccine was the direct cause of the disease.98 This finding controverted
expert testimony that the infecting viral strain was not the vaccine strain,
that it appeared to be a wild seed, and that the child's vaccination oc-
curred during a polio outbreak in the area.99
Similarly, courts have shown a tendency to hold DPT vaccine man-
ufacturers liable for injuries in spite of a scarcity of scientific evidence
linking pertussis vaccine and severe neurological disorders." In Toner
11,101 the court found that the DPT vaccine caused transverse myelitis
just as the swine flu vaccine was found to be the cause of transverse my-
elitis in Unthank v. United States. 2 The only conclusion the vaccine
90. See generally Edmund W. Kitch, The Vaccine Dilemma, ISSUES IN SCI. AND TECH., Winter
1986, at 108. The Sabin oral polio vaccine and the measles, mumps, rubella, and rabies vaccines are
now made by sole suppliers. Id. at 108. This situation produces several unsatisfactory results. Un-
expected difficulties in production can produce shortages and increase prices. Also, the risk associ-
ated with safety of the vaccine increases. As a result, the immunization programs responsible for
reducing the incidence of paralytic polio from 57,000 in 1952 to 4 in 1984, and the incidence of
measles from 894,134 reported cases and 2,250 deaths in 1941 to 1,497 reported cases and 2 deaths
in 1983, have been seriously jeopardized. Id. 108-11.
91. Richard J. Mahoney & Stephen E. Littlejohn, Innovation on Trial: Punitive Damages Ver-
sus New Products, 246 SCIENCE 1395 (1989). The shift from negligence to strict liability has served
to generate added lawsuits. Id. The potential for huge punitive damages assessed against drug man-
ufacturers, regardless of the attention paid to maximizing safety, has created a level of uncertainty
that cannot be managed along with innovation. Id.
92. See Garrett, supra note 6, at 5.
93. See supra notes 50-68 and accompanying text.
94. See supra notes 50-68 and accompanying text.
95. Mahoney & Littlejohn, supra note 91, at 1396.
96. Earley, supra note 19, at 358-61.
97. 498 F.2d 1264 (5th Cir. 1974), cert. denied, 419 U.S. 1096 (1974).
98. Id. at 1271. See Farley, supra note 19, at 358.
99. See Earley, supra note 19, at 358.
100. See id. at 360.
101. 828 F.2d 510, 514 (9th Cir. 1987).
102. 732 F.2d 1517, 1518 (10th Cir. 1984).
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manufacturers and researchers can draw from these decisions is that the
legal system is predisposed to attribute a plaintiff's injury to vaccines
even in the face of contradictory scientific evidence.10 3 It thus appears
that the courts have been compensating victims, who have no other
means of recovering expenses,"° by awarding verdicts against manufac-
turers at the ultimate expense of scientific and medical innovation.
The production of vaccines, a marginal commercial proposition at
best, has become a clearly unattractive undertaking given the expense
and risk of litigation.105 In terms of the effect of tort liability on the
development of an AIDS vaccine, "those threatened with [AIDS], who
understand that profit is a remarkably powerful incentive for innovation,
must view the situation as an all but criminal disaster."' 0 6
B. Problems Presented by the Federal Legislative Efforts
The cases brought against the United States under the Swine Flu
Act of 1976 increased manufacturers' concern.10 7 Although supposedly
immune from liability by the provisions of the Act, 08 at least one
court0 9 nonetheless held the manufacturer strictly liable for marketing a
defective product, a vaccine which inadequately warned the ultimate
consumer of the risks and potential side effects associated with the vac-
cine. 110 In other words, the manufacturer, not the government, assumed
liability for any resulting inadequacies of the warning. This decision
could be viewed by manufacturers as imposing "so stringent a warning
requirement as likely to render any future mass inoculation program in-
feasible, no matter how desirable.""'
Decisions under the Swine Flu Act led manufacturers to observe
that the courts again appeared predisposed to stretch the issue of causa-
tion. Most claims involved injuries attributable to Guillian-Barre Syn-
drome (GBS). 12 According to a CDC study, the occurrence of GBS
103. See Earley, supra note 19, at 361.
104. See generally Prins-Stairs, supra note 46, at 704, 725; Kitch, supra note 90, at 109.
105. Kitch, supra note 90, at 111.
106. PETER W. HUBER, LIABILrry: THE LEGAL REVOLUTION AND ITS CONSEQUENCES 230
(1988).
107. See Rosenfeld, supra note 69, at 199.
108. 42 U.S.C. § 247b(k)(1)(A) (1976) (amended 1978).
109. Petty v. United States, 740 F.2d 1428 (8th Cir. 1984).
110. Id. at 1440-41. The court noted, however, that its decision did not defeat the intent of the
Act, which is to prevent exposure of manufacturers to unlimited liability. Id. The government still
had the burden of defending the action as well as bearing the resulting damages. Id. at 1441 n.12.
111. Id. at 1442 (Bright, J., dissenting).
112. Rosenfeld, supra note 69, at 199. Unexpectedly, the vaccine was linked to the occurrence of
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attributable to the swine flu vaccine could not be distinguished from the
background incidence." 3 In other words, the incidence of GBS among
the population receiving the vaccine was indistinguishable from the inci-
dence rate of the general population. Vaccine status may not have been a
relevant factor at all. Although this issue of causation received little at-
tention from the courts, compensation by the government, "nearly $80
million on about 700 claims," was regarded as fair since the government
had strongly urged participation in the vaccination program.' 14 How-
ever, vaccine manufacturers viewed the courts' handling of the causation
issue with disapproval and increased concern for the future of vaccine
development, 15 a particularly ominous attitude given the subsequent ap-
pearance of the AIDS virus.
In spite of the problems encountered with interpretation of the
Swine Flu Act, it provided a model for future legislation at the Federal
level. The Act underscored the need both to protect the vaccine manu-
facturer from becoming the vaccinee's insurer against injury and to as-
sure the vaccinee that compensation would be available for injuries
resulting from adverse reactions to the vaccine or its administration." t6
The GBS cases also suggested the need to impose restrictions within the
legislation on the time elapsed between vaccination and the onset of dis-
ease symptoms alleged to be attributable to the vaccine. 17
The second Congressional enactment aimed at relieving vaccine
manufacturers liability, the NCVIA, has been criticized on three princi-
pal grounds." 8 First, funding legislation was not enacted until Decem-
ber 22, 1987, and the Act did not become effective until October 1,
1988.119 In other words, the Act remained a mere "paper transaction"
for over a year since Congress failed to identify a source of funds ini-
tially. 20 Second, the potential for tort liability remains a threat to the
a neurological condition, GBS, which resulted in paralysis in approximately one out of 100,000
vaccine recipients. Id.
113. Kitch, supra note 90, at 116.
114. Id.
115. Id. at 120.
116. Marc A. Franklin & Joseph E. Mais, Jr., Tort Law and Mass Immunization Programs:
Lessons from the Polio and Flu Episodes, 65 CAL. L. REV. 754, 773-74 (1977).
117. See Kitch, supra note 90, at 116 (discussing the government's stipulation that its acceptance
of liability was contingent upon the onset of GBS symptoms within 10 weeks of vaccine
administration).
118. See Rosenfeld, supra note 69, at 198.
119. See Prins-Stairs, supra note 46, at 735.
120. See Okianer C. Dark, Is the National Childhood Vaccine Injury Act of 1986 the Solution for
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manufacturer if the applicant is not satisfied with the award available
from the compensation fund.121 Finally, the NCVIA does not eliminate
the potential for state tort action against the manufacturer. 122
Application of the NCVIA to the injuries likely to occur with the
eventual AIDS vaccine emphasizes the Act's limitations. One of the
more innovative provisions of the Act, the Vaccine Injury Table,12 3 pre-
cisely defines the time period in which the first symptoms or manifesta-
tion of onset of injuries must occur after vaccine administration in order
for a vaccinee to receive compensation under the Act. Although critical
to the dual purposes of insuring compensation for injuries attributable to
vaccines while eliminating complaints of injury with no medical or scien-
tific merit, this type of Injury Table would be extremely difficult to apply
in the case of AIDS. Given the highly variable and comparatively long
time lag 124 typical of the progression of AIDS, 125 the merit of such an
injury table becomes questionable. The failure of the NCVIA to elimi-
nate the possibility of state tort liability would leave the manufacturers of
an AIDS vaccine open to the interpretive whims of state courts. This
result could be eliminated if Congress specifically immunizes the manu-
facturers from liability for any unavoidable side effects of the vaccine. 126
Any legislation enacted at the Federal level to address the questions
of the liability of AIDS vaccine manufacturers and compensation of vic-
tims should reflect the specific conditions posed by AIDS as well as suc-
cesses and failures of previous legislative attempts in this area, the Swine
Flu Act of 1976 and the NCVIA of 1986. For example, the definition of
compensable injuries under the ideal act, by necessity, would be broader
than those in the Vaccine Injury Table of the NCVIA. Also, the ideal
act must define an adequate source of funds for a Compensation Fund
and specifically provide immunity for the vaccine manufacturers from
121. See Rosenfeld, supra note 69, at 198. If a compensation fund applicant is unsatisfied with
the level of compensation received, the applicant may seek damages from the manufacturer for its
negligence. Id.
122. Id.
123. 42 U.S.C.A. § 300aa-14.
124. While the time lag between vaccination and the onset of symptoms of adverse reactions is
twenty-four hours to three days for the DPT vaccine, twenty-four hours to fifteen days for the mea-
sles, mumps, and rubella vaccine, and twenty-four hours (anaphylaxis) or thirty days to six months
(paralytic polio) for the polio vaccines, the observed time period between infection with HIV and the
onset of disease symptoms may be up to ten years for AIDS.
125. The CDC has categorized the stages of AIDS with great precision. See Centers for Disease
Control, Human Immunodeficiency Virus (HITV Infection Codes: Official Authorized Addendum
ICD-9-CM, 36 MORBIDITY & MORTALITY WKLY. RE'. Supp. 7 (1987).
126. See Prins-Stairs, supra note 46, at 737.
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state tort actions, the source of legal uncertainty for past vaccine
manufacturers.
C. The California and Connecticut Statutes
Recognition of the urgency posed by the threat of AIDS, 127 the con-
comitant need for research to develop a vaccine, and the failure of the
federal government to provide legislation adequate to protect the manu-
facturers by preemption of state tort liability 128 prompted the California
and Connecticut legislatures to take action aimed directly at resolving
tort liability and the manufacture of an AIDS vaccine. These efforts pro-
vide a starting point in an area where legislation is critically needed.
The ultimate aim of the California statute is to shield the manufac-
turer of an FDA-approved AIDS vaccine from tort liability while com-
pensating the injured plaintiff with funds drawn from the AIDS Vaccine
Victim's Compensation Fund.129 The strengths of the legislation include
the provision of the Compensation Fund with a defined source for the
funds, a surcharge placed on the sale of each unit of the vaccine. 130
Those receiving the vaccine and its benefits share the inevitable costs of
the vaccination program, compensation of inadvertent injuries. Another
component of the California statute, the AIDS Vaccine Guaranteed
Purchase Fund, should provide incentive for continued research, clinical
trials, and production of the vaccine in the state of California. 131
However, the California statute fails to protect manufacturers ade-
quately. Although it does offer protection from strict liability, the statute
127. See supra notes 7-18 and accompanying text.
128. But see Rosenfeld, supra note 69, at 201-02 n.99. Recent federal efforts address the general
liability issues facing drug manufacturers. First, § 303 of the Product Liability Reform Act, S.
1400, 101st Cong., Ist Sess. (1989), established uniform standards for the award of punitive dam-
ages. In addition, §§ 201 and 202 of the Act encourages out-of-court settlement in a reasonable
manner and for reasonable sums. Second, § 8 of the Uniform Products Liability Act of 1989, H.R.
1636, 101st Cong., Ist Sess. (1989), serves to cap punitive damages awards. Section 4 of the Act
grants immunity from civil liability to manufacturers and suppliers of products which cause harm
because of aspects of the product which cannot be made safe and are well known to the ordinary
consumer with common knowledge. Section 4 of this Act also eliminates both product design and
the failure to give an adequate warning, with an adequate warning requiring steps to warn physicians
or consumers of dangers known to exist at the time of manufacture, as defects constituting liability.
In addition, § 6(a) provides that the manufacturer would not be liable if the product "complied
materially" with design and/or labeling standards imposed by the federal government. See id.
129. See McKenna, supra note 85, at 962.
130. Id.
131. Critics of the plan to market an AIDS vaccine warn that the high costs of the vaccine itself
combined with a limited market could result in an unaffordable product. See McKenna, supra note
85, at 963. The guaranteed purchase provision serves to lessen the insecurity of the manufacturers.
Id. The state of California guaranteed a market and, therefore, an incentive for continued research
and development of an AIDS vaccine. Id.
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specifically states that the injured applicant is not barred from pursuing
claims against the fund and lawsuits against the manufacturer concur-
rently. 32 People with unsubstantiated claims could, in effect, seek com-
pensation from the "deep pocket" of the state while people with stronger
claims would not be deterred from filing civil claims in state court.133 In
addition, the California legislation applies only to injuries alleged to have
been caused by an FDA-approved vaccine sold and delivered in Califor-
nia. 134 It affords neither protection from liability nor compensation for
injuries arising during the development and testing phases prior to FDA
approval of the vaccine.
135
The Connecticut statute, introduced to the legislature at the request
of MicroGeneSys, Inc., of Meriden, Connecticut, 136 limits the liability of
manufacturers and researchers during the development of an AIDS vac-
cine only to those cases in which "gross negligence, or reckless, willful or
wanton misconduct" can be demonstrated. 137 Unlike the California stat-
ute, this legislation serves to protect those involved with the development
of an AIDS vaccine before FDA approval.1 3' The mere existence of the
statute is an acknowledgment that inadvertent injuries may occur. How-
ever, the statute fails to provide for compensation of the victims inadver-
tently injured by the vaccine. Protection of the manufacturers does not
extend beyond the research and development phase.1 39 Although the
eventual AIDS vaccine will probably be a biotech vaccine, it will not be
completely risk-free.' 4I Therefore, the potential for injuries will exist be-
yond FDA approval of the vaccine. Protection of manufacturers and
compensation of victims must also be provided for beyond FDA
approval.
The Connecticut statute also fails to provide protection for an "in-
jury" heretofore ignored. Those individuals who volunteer to participate
in clinical trials during the development of the AIDS vaccine and are
132. CAL. HEALTH & SAFETY CODE § 199.50(m) (West 1991).
133. See McKenna, supra note 85, at 963.
134. CAL. HEALTH & SAFETY CODE § 199.50(b)-(c).
135. Id. § 199.50(c)(3).
136. MicroGeneSys, Inc. is one of more than a dozen U.S. companies working on a vaccine. See
Blum, supra note 6, at 36.
137. 1991 Conn. Pub. Acts 91-349, §§ 4-8.
138. Although the statute does not require FDA approval of the vaccine, an application for an
investigational new drug must be both on file with the federal FDA and in effect. Id. § 4(1).
139. The emphasis of the Connecticut statute is clearly on research devoted to the production of
an AIDS vaccine. The statute makes no mention of protection for manufacturers after FDA ap-
proves a vaccine.
140. See Earley, supra note 19, at 365-67.
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seronegative for the presence of anti-HIV antibodies may test seroposi-
tive after participation in the clinical trials. 4 ' Although they may never
have been exposed to HIV itself, an appropriate response of their im-
mune systems to the candidate vaccine will result in the production of
anti-HIV antibodies. 42 If a clinical trial participant is tested after the
clinical trial, the test would indicate that the participant had been ex-
posed to HIV when the participant had actually been exposed to the can-
didate vaccine.' 43 These volunteers should have a guarantee of
protection from the stigma of seropositivity and its accompanying
discrimination."
The ideal statute addressing the liability of AIDS vaccine manufac-
turers would combine the most valuable portions of both the California
and Connecticut statutes. One section should address potential liability
during the research and clinical trials stages, reflecting the Connecticut
approach; 45 another section should address liability post-FDA approval
of the vaccine, reflecting the California approach.' 46 The inclusion of an
AIDS Vaccine Victims' Compensation Fund and a specified means of
generating funds for that purpose is necessary 47 to insure that any inad-
vertent injuries will be compensated. The huge medical costs required
for treatment of AIDS patients must be addressed by a Compensation
Fund. Furthermore, compensation must extend to the victim's survivors
who may bear the responsibility of treatment costs. Another area deserv-
ing attention is a guarantee of research subjects' accessibility to insurance
coverage, employment and housing opportunities, and any other rights
currently jeopardized by HIV-positive status, since an HIV-negative vol-
unteer will test positive for the presence of antibodies to the antigen
presented in the vaccine although the individual may not have been chal-
lenged by a virulent form of HIV.
141. See Tacket & Edelman, supra note 42, at 356.
142. See supra notes 20-32 and accompanying text.
143. See supra notes 20-32 and accompanying text.
144. See Levine, supra note 13, at 100. Currently, individuals who test seropositive to HIV
encounter difficulties in obtaining insurance, donating blood, joining the military, and traveling
abroad. Id. The National Institute of Allergy and Infectious Diseases (NIAID) provides documen-
tation to participants in approved clinical trials indicating that their seropositivity resulted from
participation in research trials. Id.
145. See supra notes 79-89 and accompanying text.
146. See supra notes 79-89 and accompanying text.
147. Assurance of compensation for medical costs accompanying inadvertent injuries from the
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VI. CONCLUSION
Acquired immunodeficiency syndrome has deeply affected many as-
pects of our society. The high costs, in terms of both lost lives and losses
to the economy, demand that the spread of the virus be halted. A vac-
cine is urgently needed. However, large pharmaceutical companies are
reluctant to enter the market given the risks of litigation associated with
unavoidably unsafe products, such as vaccines. Legislative action is re-
quired to protect manufacturers of an AIDS vaccine from the uncertain-
ties historically present in vaccine litigation and to insure the realization
of a vaccine. This legislation should address issues of tort liability during
both the development and testing stages of the vaccine as well as post-
FDA approval of the vaccine. The legislation should also provide for the
existence of a victims' compensation fund and a source for its funding.
Helen Holt Blake
19
Blake: The AIDS Vaccine: Legislation to Limit Manufacturer's Liability
Published by TU Law Digital Commons, 1991
20
Tulsa Law Review, Vol. 27 [1991], Iss. 4, Art. 13
https://digitalcommons.law.utulsa.edu/tlr/vol27/iss4/13
